Hypereosinophilia of persistent/unknown cause: a bone marrow–based study integrating WHO-HAEM5 criteria and myeloid next-generation sequencing
American Journal of Clinical Pathology · 05.05.2026 · 165 (5)
DOI: 10.1093/ajcp/aqag031 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift American Journal of Clinical Pathology, online erschienen am 10.05.2026. Verfasst von Mohamed M Eletrebi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA, United States. Hauptthemen laut MEDLINE: Eosinophilia, Hypereosinophilic Syndrome, Hematologic Neoplasms, High-Throughput Nucleotide Sequencing. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Pathology at the University of Iowa Health Care.
Abstract (Originalsprache)
Objectives
Hypereosinophilia (HE), defined as an absolute eosinophil count (AEC) ≥1.5 × 109/L, poses diagnostic challenges when distinguishing clonal myeloid neoplasms from idiopathic HE/hypereosinophilic syndrome, particularly under WHO-HAEM5 criteria. We characterized patients with HE of persistent/unknown cause (HEPU) undergoing bone marrow (BM) evaluation to refine diagnostic classification.
Methods
We identified 307 BM biopsy specimens (2015-2023) mentioning “eosinophilia.” Patients with defined reactive or clonal etiologies were classified as group 2 (known etiology, n = 269). The remaining patients constituted group 1 (HEPU, n = 38). We reviewed clinical data, morphology, cytogenetics/fluorescence in situ hybridization (FISH), and myeloid next-generation sequencing (NGS), assigning final diagnoses via the fifth edition of the World Health Organization Classification of Haematolymphoid Tumours (WHO-HAEM5) criteria and the 2022 International Consensus Classification (ICC).
Results
Compared to group 2, patients with HEPU were younger (median 48 vs 62 years; P = .004) and exhibited higher initial AECs (2.8 vs 0.6 × 109/L; P < .001). Comprehensive workup reclassified the HEPU cohort (n = 38) into the idiopathic spectrum (36.8%), reactive eosinophilia (28.9%), clonal disorders including myeloid and lymphoid neoplasms (28.9%), and mixed reactive vs idiopathic (5.3%) categories. While cytogenetics/FISH were largely noncontributory (detecting FIP1L1::PDGFRA in 2 cases), myeloid NGS detected mutations in 47% (7/15) of tested patients with HEPU, involving genes such as TP53, BCOR, SF3B1, and TET2.
Conclusions
Integrated clinicopathologic and molecular assessment reclassified most HEPU cases as reactive or clonal, with only 39% remaining idiopathic. Myeloid NGS frequently identifies clonal variants critical for refining HE classification, although results require cautious interpretation within the WHO-HAEM5 and ICC 2022 context.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA, United States.
ORCID-Profile: Mohamed M Eletrebi, Carol J Holman
Förderung
- Department of Pathology at the University of Iowa Health Care
Zitieren
APA
Eletrebi, M. M., Sanchez-Ramirez, J., Abdalla, A., & Holman, C. J. (2026). Hypereosinophilia of persistent/unknown cause: a bone marrow–based study integrating WHO-HAEM5 criteria and myeloid next-generation sequencing. American Journal of Clinical Pathology, 165(5). https://doi.org/10.1093/ajcp/aqag031
Vancouver
Eletrebi MM, Sanchez-Ramirez J, Abdalla A, Holman CJ. Hypereosinophilia of persistent/unknown cause: a bone marrow–based study integrating WHO-HAEM5 criteria and myeloid next-generation sequencing. American Journal of Clinical Pathology. 2026;165(5). doi:10.1093/ajcp/aqag031
BibTeX
@article{Eletrebi2026,
author = {Eletrebi, Mohamed M and Sanchez-Ramirez, Juan and Abdalla, Abdalla and Holman, Carol J},
title = {Hypereosinophilia of persistent/unknown cause: a bone marrow–based study integrating WHO-HAEM5 criteria and myeloid next-generation sequencing},
journal = {American Journal of Clinical Pathology},
year = {2026},
volume = {165},
number = {5},
doi = {10.1093/ajcp/aqag031}
}
EUVIMED